Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Marc Lemaître, Keith Regnante, and James Frontero

Marc Lemaître

Link has appointed Marc Lemaître as chairman of the board. He takes over from Mick McLean, who is stepping down after nine years in the role. Lemaître currently works as an independent consultant, although he joined Link in 2015 as a non-executive director. He has also worked for Glen Research and served as CEO of Grindus America.

Keith Regnante

Wave Life Sciences has appointed Keith Regnante as its CFO. Regnante comes to Wave from Shire, where he served as vice president of finance. Prior to Shire, he held a number of positions of increasing responsibility at Biogen. Earlier in his career, Regnante worked as a consultant with the Boston Consulting Group.

James Frontero

Good Start Genetics has appointed James Frontero as chief commercial officer. Before joining Good Start, Frontero served as senior vice president of sales and commercial operations at Devicor Medical Products. Prior to his work at Devicor, he served as president of Straumann USA and held numerous sales and sales leadership roles within Boston Scientific.

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.